Human Exhausted T Cell Antibody Sampler Kit #81490
Product Information
Kit Usage Information
Protocols
- 2203: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence, Flow, ChIP Magnetic
- 7074: Western Blotting
- 15372: Western Blotting, Immunohistochemistry (Leica® Bond™), Immunohistochemistry (Paraffin)
- 36778: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence, Immunofluorescence, Flow, ChIP Magnetic
- 45208: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Leica® Bond™), Immunohistochemistry (Paraffin), Flow Cytometry Live Cell Unconjugated Rabbit
- 54560: Western Blotting, Immunoprecipitation (Agarose)
- 81493: Western Blotting, Immunofluorescence, Flow, Sonication Chromatin Immunoprecipitation Protocol, CUT&RUN Assay
- 86163: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Leica® Bond™), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 96399: Western Blotting, Immunoprecipitation (Magnetic)
- 99567: Western Blotting, Immunohistochemistry (Paraffin), Immunofluorescence*
Product Description
The Human Exhausted T Cell Antibody Sampler Kit provides an economical means of characterizing the extent of exhaustion in T cells. This kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Specificity / Sensitivity
Each antibody in the Human Exhausted T Cell Antibody Sampler Kit detects endogenous levels of its target human protein. Tox/Tox2 (E6G5O) Rabbit mAb does not cross-react with Tox3 or Tox4 proteins, but does cross-react with an unidentified protein of 50 kDa in some murine cell extracts. TCF1/TCF7 (C63D9) Rabbit mAb does not recognize the dominant negative isoforms of TCF1/TCF7 lacking the amino-terminal β-catenin binding domain and does not cross-react with LEF1. TIGIT (E5Y1W) XP® Rabbit mAb cross-reacts with an unidentified protein of 42 kDa in some cell extracts. 2B4/SLAMF4/CD244 (D5J9D) Rabbit mAb cross-reacts with an unidentified protein of 18 kDa in some cell extracts.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln435 of human Tox protein, Pro96 of human TCF1/TCF7 protein, Pro180 of human EOMES protein, Ala274 of human PD-1 protein, Leu95 of human CTLA-4 protein, and Asp367 of human 2B4/SLAMF4/CD244 protein. Monoclonal antibodies are produced by immunizing animals with a recombinant protein specific to the carboxy terminus of human TIGIT protein, the extracellular domain of human TIM-3 protein, and the amino terminus of human LAG3 protein.
Background
Tox, TCF1/TCF7, and EOMES play key roles in T cell development. Tox is also induced by high antigen stimulation during chronic viral infection or cancer, regulating T cell persistence and exhaustion. TCF1/TCF7 preserves the effector function of exhausted T cells during viral infection or cancer. EOMES is a key transcription factor for memory T cells and for full effector differentiation of CD8+ T cells. Expression of EOMES is induced in CD8+ T cells following viral infection and bacterial infection, and high levels of EOMES promotes T cell exhaustion. The dynamic expression of these transcription factors help characterize the extent to which a T cell is exhausted and will respond to antigen stimulation (1-5)
PD-1 (PDCD1, CD279), CTLA-4 (CD152), TIGIT (VSIG9, VSTM3), TIM-3 (HAVCR2), LAG3 (CD223), and 2B4 (SLAMF4, CD244) are immune cell co-inhibitory receptors (also known as immune checkpoints) that negatively regulate T cell function and dampen the immune response to pathogens and cancer. In addition to activated T cells, PD-1 is expressed by activated B cells and monocytes. Following interaction with its ligands, PD-L1 and PD-L2, PD-1 is phosphorylated at ITIM and ITSM motifs leading to recruitment of protein tyrosine phosphatases SHP-1 and SHP-2 and suppression of TCR signaling. CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells. CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, resulting in downregulation of T cell activity. TIGIT is expressed at low levels on subsets of T cells and natural killer (NK) cells, and is upregulated at the protein level following activation of these cells. TIGIT marks exhausted T cells in the tumor microenvironment and during human immunodeficiency virus (HIV) infection. TIM-3 is expressed by exhausted T cells in the settings of chronic infection and cancer. Tumor-infiltrating macrophages and dendritic cells also express TIM-3. LAG3 is primarily expressed by activated CD4+ T cells, CD8+ T cells, FoxP3+ T regulatory cells (Tregs), and NK cells. 2B4 is a heterophilic cell surface receptor expressed on a variety of immune cells, including NK cells, T cells, eosinophils, mast cells, and dendritic cells. 2B4 has been shown to have both immune stimulatory and inhibitory effects on cells. Co-expression of multiple immune checkpoints help characterize the extent to which a T cell is exhausted and will respond to antigen stimulation. Therapeutic blockade of several of these immune checkpoint receptors is a promising strategy for neoplastic intervention by enabling anti-tumor immune responses (6-13).
PD-1 (PDCD1, CD279), CTLA-4 (CD152), TIGIT (VSIG9, VSTM3), TIM-3 (HAVCR2), LAG3 (CD223), and 2B4 (SLAMF4, CD244) are immune cell co-inhibitory receptors (also known as immune checkpoints) that negatively regulate T cell function and dampen the immune response to pathogens and cancer. In addition to activated T cells, PD-1 is expressed by activated B cells and monocytes. Following interaction with its ligands, PD-L1 and PD-L2, PD-1 is phosphorylated at ITIM and ITSM motifs leading to recruitment of protein tyrosine phosphatases SHP-1 and SHP-2 and suppression of TCR signaling. CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells. CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, resulting in downregulation of T cell activity. TIGIT is expressed at low levels on subsets of T cells and natural killer (NK) cells, and is upregulated at the protein level following activation of these cells. TIGIT marks exhausted T cells in the tumor microenvironment and during human immunodeficiency virus (HIV) infection. TIM-3 is expressed by exhausted T cells in the settings of chronic infection and cancer. Tumor-infiltrating macrophages and dendritic cells also express TIM-3. LAG3 is primarily expressed by activated CD4+ T cells, CD8+ T cells, FoxP3+ T regulatory cells (Tregs), and NK cells. 2B4 is a heterophilic cell surface receptor expressed on a variety of immune cells, including NK cells, T cells, eosinophils, mast cells, and dendritic cells. 2B4 has been shown to have both immune stimulatory and inhibitory effects on cells. Co-expression of multiple immune checkpoints help characterize the extent to which a T cell is exhausted and will respond to antigen stimulation. Therapeutic blockade of several of these immune checkpoint receptors is a promising strategy for neoplastic intervention by enabling anti-tumor immune responses (6-13).
- Aliahmad, P. et al. (2012) Curr Opin Immunol 24, 173-7.
- Yao, C. et al. (2019) Nat Immunol 20, 890-901.
- Alfei, F. et al. (2019) Nature 571, 265-269.
- Wang, Y. et al. (2019) Front Immunol 10, 169.
- Li, J. et al. (2018) Front Immunol 9, 2981.
- Schildberg, F.A. et al. (2016) Immunity 44, 955-72.
- Anderson, A.C. et al. (2016) Immunity 44, 989-1004.
- Callahan, M.K. et al. (2016) Immunity 44, 1069-78.
- Ward-Kavanagh, L.K. et al. (2016) Immunity 44, 1005-19.
- Chen, L. and Flies, D.B. (2013) Nat Rev Immunol 13, 227-42.
- Sivori, S. et al. (2002) Proc Natl Acad Sci U S A 99, 4526-31.
- Chauvin, J.M. et al. (2015) J Clin Invest 125, 2046-58.
- Chew, G.M. et al. (2016) PLoS Pathog 12, e1005349.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.